Article Sidebar

pdf
Date Published: 21/04/2025
Abstract Views: 91
Views pdf: 44
DOI: https://doi.org/10.51298/vmj.v549i1.13596
Issue
Vol. 549 No. 1 (2025)
Section
Các bài báo
How to Cite
Trương Quang, H., Nguyễn Trọng, N., & Phan Trung, H. (2025). THE SUCCESS RATE OF MTX/FA FOR TREATMENT OF GESTATIONAL TROPHOBLASTIC NEOPLASIA WITH RISK SCORE ≤6 AT TU DU HOSPITAL. Vietnam Medical Journal, 549(1). https://doi.org/10.51298/vmj.v549i1.13596

THE SUCCESS RATE OF MTX/FA FOR TREATMENT OF GESTATIONAL TROPHOBLASTIC NEOPLASIA WITH RISK SCORE ≤6 AT TU DU HOSPITAL

Hưng Trương Quang, Nhân Nguyễn Trọng, Hòa Phan Trung

Main Article Content

Abstract

Objective: This study aimed to determine the success rate of the MTX/FA regimen in the treatment of gestational trophoblastic neoplasia with a risk score ≤ 6 and related factors at Tu Du Hospital. Method: A retrospective cross-sectional study involving 283 patients treated at Tu Du Hospital from February 2019 to December 2022. Results: Results: The MTX/FA regimen has a success rate in the treatment of gestational trophoblastic neoplasia with a risk score of 0-6 of 72.80%. Factors related to the success rate of the regimen: patients with βhCG levels ≥10,000 mIU/ml had a 57.51-fold higher risk of failure with the MTX/FA regimen than patients with βhCG levels <1,000 mIU/ml (p < 0.001). Patients with the largest tumor size ≥3 cm had a 3.17-fold higher risk of resistance to MTX/FA chemotherapy than those with tumor size <3 cm (p = 0.016). Conclusion: the MTX/FA regimen is still the optimal choice in treating gestational trophoblastic neoplasia with a FIGO risk score of 0-6 points.

Article Details

Keywords

gestational trophoblastic neoplasia, risk score, MTX/FA regimen

References

1. Management of Gestational Trophoblastic Disease: Green‐top Guideline No. 38 – June 2020. BJOG: Int J Obstet Gy. 2021;128(3). doi:10.1111/1471-0528.16266
2. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l-1. Br J Cancer. 2010;102(5):810-814. doi:10.1038/sj.bjc. 6605529
3. Võ Thành N. Nồng độ β-hCG huyết thanh có liên quan đến kết cục điều trị TSNBN nguy cơ thấp hậu thai trứng của phác đồ Methotrexate - Folinic acid (MTX - FA) không? 2020.
4. Goldstein DP, Berkowitz RS. Current Management of Gestational Trophoblastic Neoplasia. Hematology/Oncology Clinics of North America. 2012;26(1): 111-131. doi:10.1016/j.hoc. 2011.10.007
5. Mangili G, Cioffi R, Danese S, et al. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. Gynecologic Oncology. 2018; 151(3):449-452.doi:10.1016/j.ygyno. 2018.09.025
6. Lê Sỹ P. Đánh giá hiệu quả của phác đồ MTX/FA trong điều trị u nguyên bào nuôi nguy cơ thấp theo FIGO 2000 và các yếu tố tiên lượng kháng thuốc. Tập san Y học TPHCM. 2021;13(2):53-62
7. Lybol C, Sweep FCGJ, Harvey R, et al. Relapse rates after two versus three
consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecologic Oncology. 2012;125(3): 576-579. doi:10.1016/j.ygyno.2012.03.003
8. Nguyễn Thái G. Kết quả điều trị bệnh nhân u nguyên bào nuôi nguy cơ tháp tại bệnh viện Phụ Sản Trung ương. Tạp Chí Nghiên Cứu Y Học. 2019
9. Uberti EMH, Fajardo M do C, Cunha AGV da, Frota SS, Braga A, Ayub ACK. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37(6): 258-265. doi:10.1590/SO100-720320150005366